Abstract:
Disclosed are biomaterials, including engineered living materials (ELMs), comprising a plurality of microbial cells, wherein the material has a Young's Modulus of at least 5 Gpa; and methods of fabricating said biomaterials.
Abstract:
Disclosed are biomaterials, including engineered living materials (ELMs), comprising a plurality of microbial cells, wherein the material has a Young's Modulus of at least 5 Gpa; and methods of fabricating said biomaterials.
Abstract:
Disclosed are methods for producing genetically modified bacteria, comprising introducing into said bacteria at least one engineered cryptic plasmid comprising a heterologous nucleic acid, wherein the heterologous nucleic acid comprises a nucleic acid sequence encoding a recombinant protein and a polypeptide secretion system for directing the recombinant protein to the outer membrane for secretion, wherein the bacteria do not comprise any native cryptic plasmids.
Abstract:
The present invention provides refillable drug delivery systems, as well as methods of refilling the systems, and methods of using them to treat diseases.
Abstract:
The present invention provides refillable drug delivery devices. The invention is based in part on the development of systemically administered drug payloads that home to and refill resident, e.g., previously administered/implanted, drug delivery systems, e.g., hydrogel drug delivery systems. In one aspect, the drug delivery depots of the invention are systemically administered, e.g., enterally administered or parenterally administered. The invention provides a method of nanotherapeutic drug delivery, e.g., a DNA nanotechnology-based approach for blood-based drug refilling of intra-tumor drug depots.
Abstract:
The present invention provides refillable drug delivery systems, as well as methods of refilling the systems, and methods of using them to treat diseases.
Abstract:
Embodiments of the present disclosure are directed to methods of genetically modifying bacteria to create amyloid-based materials, such as biofilms created by amyloid fibers, having nonnative functional polypeptides expressed thereon and connected thereto by a linker domain optimized for functioning of the non-native functional polypeptides. According to one aspect, the linker domain is optimized for functioning of a CsgA protein as is it assembled into an amyloid state and for functioning of the functional polypeptide. Exemplary biofilms may include living bacterial cells, non-living bacterial cells or combinations of living bacterial cells and non-living bacterial cells. Methods of making biofilms having non-native functional polypeptides attached thereto are provided.